Company intelligence / Profile preview

Jocasta Neuroscience

Scottsdale, Arizona, USAjocastaneuro.com ↗

Ownership: Private
Development stage: Other

Overview

Jocasta Neuroscience is advancing a synthetic subcutaneous formulation of α-Klotho protein (JN-0413) with demonstrated robust cognitive enhancement in animal models across multiple species and cognitive tasks. Human trials are expected to begin in 2026, pending IND submission slated for late 2026[1][6][7][8][9].

Therapeutic areas: Neurology
Modalities: ProteinRecombinant protein
Industry: Biotech

Drug pipeline

1 asset

JN-04133

Pre-clinical

Indications: Cognitive decline, Age-related cognitive impairment

Beyond the preview

Go deeper on Jocasta Neuroscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jocasta Neuroscience.

Explore the full profile